Global GLP-1 Agonist Market Trends

New information was discussed on the global glucagon-like peptide 1 (GLP-1) agonist market in a recent report published by ResearchAndMarkets. The GLP-1 market has shown a steady increase of 20.6% CAGR between 2020 and 2023. In 2022, this market was worth 18.75 billion and experts predict it will reach 133.5 billion by 2030. The updated market research report included economic information from all over the world, such as the United States, Canada, Germany, France, etc. As well as the size of the markets, predictions for yearly growth and analysis, market competition, investment opportunities, and what the demand will look like in the coming years. The report also analyzed indicators for growth, potential setbacks, and risks for supply and demand. They also assessed trends for the current market and the future market.

Furthermore, both developed and developing regions around the globe have increased demand for GLP-1 agonists. A rise in type 2 diabetes mellitus (T2DM) is most prevalent in emerging economies, which highlights a need for effective management strategies for patients with diabetes. Short-acting and long-acting GLP-1 agonist drugs are both desirable options for patients and health care providers and are administered orally and through subcutaneous injection. GLP-1 agonists are sought after because of their effectiveness in glycemic control for patients with T2DM, lowering plasma glucose levels, and weight loss.

Researchers also found that GLP-1 agonists benefit patients with cardiovascular issues. The drug can reduce major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular deaths. Health care professionals recommend a GLP-1 agonist for heart-related its benefits for patients with T2DM and a previously diagnosed cardiovascular disease.

Researchers are developing further alternatives for administering GLP-1 agonists, such as oral and once-weekly injections. This way, patients have more alternatives that work for their lifestyle and can adhere to their doctor’s medication recommendations. As GLP-1 agonists are researched further and make more improvements, patients will have higher levels of satisfaction, and the market will see more use and economic growth with the drug.

Reference

Wood L. Global glucagon-like peptide 1 (GLP-1) agonist (tirzepatide, semaglutide, dulaglutide, others) market research report 2024. Yahoo! Finance. February 26, 2024. Accessed March 1, 2024. https://finance.yahoo.com/news/global-glucagon-peptide-1-glp-162400094.html